Clopidogrel drug data and news

Clopidogrel drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.

Generic name

Clopidogrel

Brand Names/Synonyms

CLOPIDOGREL SULFATE; Clopidogrel; Clopidogrel [Ban:Inn]; Plavix

Indication

For the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease

Sponsored links

Description

Not Available

Pharmacology

Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to reduce atherosclerotic events such as myocardial infarction, stroke, and vascular death in patients who have had a recent stroke, recent MI, or have established peripheral vascular disease.

Mechanism Of Action

The active metabolite of Clopidogrel prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. It is proposed that the inhibition involves a defect in the mobilization from the storage sites of the platelet granules to the outer membrane. No direct interference occurs with the GPIIb/IIIa receptor. As the glycoprotein GPIIb/IIIa complex is the major receptor for fibrinogen, its impaired activation prevents fibrinogen binding to platelets and inhibits platelet aggregation. By blocking the amplification of platelet activation by released ADP, platelet aggregation induced by agonists other than ADP is also inhibited by the active metabolite of Clopidogrel.

Clopidogrel News
(When available)

Natrecor Heart Drug - Deadly and Expensive Mar 2, 2006
..."We found that there is a 40 to 50 percent higher risk of worsening kidney function when people are treated with nesiritide than when people are treated with ... - OpEdNews

UPDATE 2-US Medicare denies some J&J heart drug coverage Mar 2, 2006
Medicare officials said they had also talked to the company about clinical trials of the drug, known generically as nesiritide. ... - Reuters

Abelson-Taylor Announces New Executive Appointments Feb 27, 2006
...agency in 1999, she has worked on a wide variety of assignments, including Actos® (pioglitazone HCl.) for type 2 diabetes; Natrecor® (nesiritide) IV infusion ... - PharmaLive.com (press release),

Head-to-Head Trials Published in the Third Quarter of 2005 ... Feb 2, 2006
Scios's Natrecor (nesiritide) saw its sales drop amid controversy about its widespread, off-label use in the United States in outpatients. ... - International News Service,

Biotechnology Industry Veteran Richard Brewer Joins SRI ... Jan 9, 2006
Previously, Mr. Brewer was CEO and President of Scios Inc., where he led the company in achieving FDA approval for Natrecor(R) (Nesiritide), the first new drug ... - Genetic Engineering News,

Off-Label Use of Blood Clotting Drug, NovoSeven, Linked to Deaths ... Jan 19, 2006
Natrecor, or nesiritide, was approved by the FDA in 2001 to treat congestive heart failure or acute decompensating heart failure in which patients experience ... - Newsinferno.com,

Increased Serum Creatinine More Likely when Nesiritide is Combined ... Nov 16, 2005
DALLAS, TX -- November 16, 2005 -- Patients with acute decompensated heart failure who receive nesiritide plus high-dose diuretics have an increased risk of ... - DG News

Follow-on Biological Products — Legal Issues Nov 15, 2005
The peptides of intermediate complexity contain 20-50 amino acids, and include insulin, glucagon, teriparatide, nesiritide, enfuvirtide, refludan, and ... - Mondaq News Alerts,

Advances in the treatment of heart failure Nov 8, 2005
...that. Nesiritide (Natrecor) is a powerful intravenous drug that relaxes blood vessels and helps make the heart beat stronger. It ... - ITP.net,

- By Theodore Dalrymple Sep 10, 2005
Last month it drew attention to the fact that a company called Scios was aggressively marketing a drug for intravenous use, Nesiritide, that cost $500 per dose ... - The Asian Age,

Dosage Forms

round, biconvex, film- coated tablet

Drug_Category

Antiplatelet Agents; Platelet Aggregation Inhibitors; Fibrinolytic Agents; ATC:B01AC04

Absorption

at least 50%

Interactions

Aspirin, warfarin, heparin, NSAIDs

Toxicity

Symptoms of acute toxicity were vomiting (in baboons), prostration, difficult breathing, and gastrointestinal hemorrhage in all species

Organisms Affected

Humans and other mammals

Chemical IUPAC Name

methyl2-(2-chlorophenyl)-2-(7-thia-3-azabicyclo[4.3.0]nona-8,10-dien-3-yl)ethanoate

Chemical Formula

C16H16ClNO2S

Molecular Weight

321.822 g/mol

Smiles String

COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3

Melting Point

158°C

Water Solubility

50.78 mg/L

State

solid

LogP/Hphobicity

Not Available

Isoelectric Point

Not Available

Biotransformation

hepatic

Half Life

11 days

Protein Binding [%]

98%

RxList Link

RXlist

Sponsored links

Drug Reference

http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/pla1338.shtml
http://www.drugs.com/cons/Clopidogrel.html
http://www.rxlist.com/cgi/generic/clopidog.htm

Drug Type

Approved Drug

Accession No

APRD00444

CAS Registry Number

113665-84-2

KEGG Compound ID

C07929

PubChem ID

SID:63924

PharmGKB ID

PA449053

SwissProt ID

Not Available

GenBank ID

Not Available

Drug ID Number [DIN]

2238682